Ornidazole

Summary

Ornidazole (CHEMBL1449676) is an approved small-molecule antiprotozoal drug (ATC G01AF06); indicated across 4 conditions including bacterial infectious disease and amebiasis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: G01AF06 (+2 more)
• Indications: 4 conditions
• Clinical trials: 6
• Chemistry: 219.62 Da · C7H10ClN3O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1449676
Name	Ornidazole
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	28061
ChEBI	CHEBI:75176
ATC	G01AF06, P01AB03, J01XD03
Molecular formula	C7H10ClN3O3
Molecular weight	219.62
InChIKey	IPWKIXLWTCNBKN-UHFFFAOYSA-N

SMILES: CC1=NC=C(N1CC(CCl)O)[N+](=O)[O-]

IUPAC name: 1-chloro-3-(2-methyl-5-nitroimidazol-1-yl)propan-2-ol

ChEBI definition: A C-nitro compound that is 5-nitroimidazole in which the hydrogens at positions 1 and 2 are replaced by 3-chloro-2-hydroxypropyl and methyl groups, respectively. It is used in the treatment of susceptible protozoal infections and for the treatment of anaerobic bacterial infections.

Pharmacological roles (ChEBI): antiprotozoal drug, antiinfective agent, antibacterial drug, antitrichomonal drug, epitope, antiamoebic agent.

Also known as: NSC-95075, Ornidazol, Ornidazole, RO-70207, Tiberal, SID855702, ORNIDAZOLE, SID170466243, SID144204133, C0164879, ornidazole

Patent coverage: 1,900 distinct patent families (5,313 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Beta-lactamase, Muscarinic acetylcholine receptor M1.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
amebiasis	4	MONDO:0005644	EFO:0007144
rectal cancer	3	MONDO:0006519	EFO:1000657
colonic neoplasm	3	MONDO:0005401	MONDO:0021063

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE3	3
Not specified	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06828874	PHASE4	COMPLETED	A Study of Levornidazole Disodium Phosphate for Injection vs. Ornidazole in Treatment of Postoperative Intra-Abdominal Infections Caused by Anaerobic Bacteria
NCT02618720	PHASE3	COMPLETED	Intravenous Versus Combined Oral and Intravenous Antimicrobial Prophylaxis for the Prevention of Surgical Site Infection in Elective Colorectal Surgery
NCT03475680	PHASE3	TERMINATED	Mechanical Bowel Preparation and Oral Antibiotics Before Colon Cancer Surgery
NCT03491540	PHASE3	COMPLETED	Mechanical Bowel Preparation and Oral Antibiotics Before Rectal Cancer Surgery
NCT06427863	Not specified	NOT_YET_RECRUITING	Effect of Antibiotic Pretreatment on the Efficacy of WMT in the Treatment of Chronic Constipation
NCT06437041	Not specified	NOT_YET_RECRUITING	Effect of Antibiotic Pretreatment on the Efficacy of WMT in the Treatment of Irritable Bowel Syndrome

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).